Abstract
This paper explores the ingredients that stimulated the development of the biotechnology industry in the US and contrasts conditions with those in Europe. It examines relationships between established firms and new start-ups; the financing and managerial environment and the organizational environment, whereby firms were able to set up networks of alliances. Its main findings are that: 1) The funding of the medical science research base has been substantially more generous in the U.S. than Europe. It is the funding of the science base rather than of the biotechnology industry directly that has provided the foundations for start-ups to be created out of the science base. 2) It has been easier for U.S. academics to found start-ups, close to their research establishment, and to retain their academic posts and status as well as be involved in a commercial enterprise. In Europe, the scientific/academic and commercial worlds have a wider divide. 3) Start-ups have been concentrated in the therapeutics and agricultural fields, with strong scientific research inputs into their commercialization, in contrast to other sectors where downstream processing innovations have been more important, which have been undertaken in-house by the large incumbent companies. 4) Financing and managerial conditions have been significantly easier in the U.S. for start-ups, in terms of access to venture capital specialising in high technology, ability to use the stock market to raise capital, and access to people able to forge links between scientists and entrepreneurs, and to introduce managerial expertise into new companies. 5) There has been a greater facility in the U.S. than in Europe for alliances to be formed between incumbent companies and indigenous U.S. start-ups; European start-ups have not found similar backing from European incumbent companies.
Similar content being viewed by others
References
Arora, A. and A. Gambardella, 1993, 'The Division of Innovative Labour in Biotechnology', in H. John Heinz III School of Public Policy and Management, Working Paper, Pittsburgh: Carnegie Mellon.
Audretsch, D. and P. Stephen, 1996, 'Company-Scientist Locational Links: The Case of Biotechnology', American Economic Review 86(3), 641-652.
Barley, S., J. Freeman and R. C. Hybels, 1992, 'Strategic Alliances in Commercial Biotechnology', in N. Nohria and R. Eccles (eds.), Networks and Organizations: Structure, Form and Action, Boston, MA: Harvard Business School Press.
Beecroft, A., 1994, 'The Role of the Venture Capital Industry in the UK', in N. Dimsdale and M. Prevezer (eds.), Capital Markets and Corporate Governance, Oxford: Oxford University Press.
Cohen, W. M. and D. A. Levinthal, 1990, 'Absorptive Capacity: A New Perspective on Learning and Innovation', Administrative Science Quarterly 35(1), 128-152.
Dibner, M. D., 1988, Bio/Technology, pp. 276-279.
Dibner, M. D., 1991, Biotechnology Guide U.S.A., Companies, Data and Analysis, New York: Macmillan.
Dimsdale, N. and M. Prevezer (eds.), 1994, Capital Markets and Corporate Governance, Oxford: Oxford University Press.
Dodgson, M., 1991, 'Strategic Alignment and Organizational Options in Biotechnology Firms', Technology Analysis and Strategic Management 3(2), 115-125.
Ernst & Young, 1992, Biotech 93: Accelerating Commercialization, San Francisco: Ernst & Young.
Ernst & Young, 1988, Biotech 89: Commercialization, San Francisco: Ernst & Young.
Giesecke, S., 2000, 'The Contrasting Roles of Government in the Development of Biotechnology Industry in the U.S. and Germany', Research Policy 29, 205-223.
Hagedoorn, J. and J. Schakenraad, 1990, 'Interfirm Partnerships and Cooperative Strategies in Core Technologies', in C. Freeman and L. Soete (eds.), New Explorations in the Economics of Technical Change, London and New York: Pinter.
Hall, S., 1987, Invisible Frontiers: The Race to Synthesize a Human Gene, London: Sidgwick and Jackson.
Kenney, M., 1986, Biotechnology: The University-Industrial Complex, New Haven, CT: Yale University Press.
Levin, R., A. Klevorick, R. Nelson and S. Winter, 1987, 'Appropriating the Returns from Industrial Research and Development', Brookings Papers on Economic Activity 3, 783-820.
McKelvey, M., 1994, Evolutionary Innovation: Early Industrial Uses of Genetic Engineering, Linkoping: Department of Technology and Social Change.
National Economic Development Office (NEDO), 1991, New Life for Industry; Biotechnology, Industry and the Community in the 1990s and Beyond, National Economic Development Council.
Orsenigo, L., 1989, The Emergence of Biotechnology, London: Pinter.
Orsenigo, L., F. Pammolli and M. Riccaboni, forthcoming, 'Technological Change and Network Dynamics. Lessons from the Pharmaceutical Industry', Research Policy.
Powell, W. and P. Brantley, 1992, 'Competitive Cooperation in Biotechnology: Learning Through Networks', in N. Nohria and R. Eccles (eds.), Networks and Organizations: Structure, Form and Action, Boston, MA: Harvard Business School Press.
Prevezer, M., 1996, 'The Dynamics of Industrial Clustering in Biotechnology', Small Business Economics 8, 1-17.
Prevezer, M. and S. Toker, 1996, 'The Degree of Integration in Strategic Alliances in Biotechnology', Technology Analysis and Strategic Management 8(2).
Prevezer, M. and S. Shohet, 1996'New Knowledge: Production v. Diffusion; the Case of U.K. Biotechnology', Centre for Business Strategy Working Paper, Number 162, London Business School.
Prevezer, M., 1998, 'Clustering in Biotechnology in the U.S.A.', in P. Swann, M. Prevezer and D. Stout (eds.), The Dynamics of Industrial Clustering. International Comparisons in Computing and Biotechnology, Oxford: Oxford University Press.
Saxenian, A., 1994, Regional Advantage, Cambridge, MA: Harvard University Press.
Sharp, M., 1985, The New Biotechnology: European Governments in Search of a Strategy, Sussex European Papers No. 15, Brighton: University of Sussex.
Sharp, M., 1991, 'Technological Trajectories and Corporate Strategies in the Diffusion of Biotechnology', in E. Deico, E. Hornell and G. Vickery (eds.), Technology and Investment: Crucial Issues for the 1990s, London: Pinter Publishers.
Shohet, S. and M. Prevezer, 1996, 'U.K. Biotechnology: Institutional Linkages, Technology Transfer and the Role of Intermediaries', R&D Management 26(3).
Swann, P., M. Prevezer and D. Stout, 1998, The Dynamics of Industrial Clustering. International Comparisons in Computing and Biotechnology, Oxford: Oxford University Press.
Teitelman R., 1989, Gene Dreams: Wall Street, Academia and the Rise of Biotechnology, New York: Basic Books Inc.
Zucker, L., M. Darby and M. Brewer, 1994, 'Intellectual Capital and the Birth of U.S. Biotechnology Enterprises', National Bureau of Economic Research Working Paper 4653, Cambridge, MA.
Zucker, L. and M. Darby, 1995, 'Virtuous Circles of Productivity: Star Bioscientists and the Institutional Transformation of Industry', National Bureau of Economic Research Working Paper 5342, Cambridge, MA.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Prevezer, M. Ingredients in the Early Development of the U.S. Biotechnology Industry. Small Business Economics 17, 17–29 (2001). https://doi.org/10.1023/A:1011174421603
Issue Date:
DOI: https://doi.org/10.1023/A:1011174421603